Patents Represented by Attorney ISIS Pharmaceuticals Patent Dept.

Find this attorney in the Justia Lawyer Directory

  • Modulation of factor 11 expression
    Patent number: 8334372
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: December 18, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Modulation of glucose-6-phosphatase translocase expression
    Patent number: 8258114
    Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: September 4, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Sanjay Bhanot
  • Modulation of glucagon receptor expression
    Patent number: 7919476
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: April 5, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lynnetta Watts, Robert McKay, Susan M. Freier
  • Compositions and methods for treatment of hepatitis C virus-associated diseases
    Patent number: 6995146
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: February 7, 2006
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
  • Antisense modulation of C-reactive protein expression
    Patent number: 6964950
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: November 15, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham